Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus tislelizumab as neoadjuvant therapy for HCC with portal vein tumor thrombosis
ChiCTR2200057978Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Event-free survival. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
tislelizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200057978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057978.